225 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast PeerView Press

    • Science
    • 5.0 • 1 Rating

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care

    Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care

    Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

    • 35 min
    Peter Goadsby, MD, PhD - Addressing Unmet Needs in the Acute Treatment of Migraine: Focus on the Role of the 5-HT1F Receptor

    Peter Goadsby, MD, PhD - Addressing Unmet Needs in the Acute Treatment of Migraine: Focus on the Role of the 5-HT1F Receptor

    Go online to PeerView.com/JDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert narration is combined with 3D animation, patient video segments, and infographic visuals for an engaging presentation on individualized migraine management, including diagnosis and treatment, the role of 5-HT1F receptor agonists for acute treatment, and consideration of patient perspectives. Upon completion of this activity, participants should be better able to: Identify individuals with migraine, including those who are appropriate candidates for acute treatment, according to current treatment recommendations, Address unmet needs in acute treatment of people with migraine, Evaluate the role of 5-HT1F receptor agonists in meeting individual needs in acute treatment of migraine.

    • 32 min
    Jonathan A. Bernstein, MD - Chronic Spontaneous Urticaria From Diagnosis to Treatment: Unique Perspectives on Employing a Multidisciplinary and Patient-Centric Approach to Care

    Jonathan A. Bernstein, MD - Chronic Spontaneous Urticaria From Diagnosis to Treatment: Unique Perspectives on Employing a Multidisciplinary and Patient-Centric Approach to Care

    Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

    • 39 min
    Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

    Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

    Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

    • 59 min
    Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

    Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

    Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon completion of this activity, participants should be better able to: Identify specific molecular and histopathologic features that can inform the diagnosis of different AML subtypes, including secondary AML/AML-MRC or FLT3- or IDH-mutant AML, Select appropriate evidence-based molecular/pathology tests to confirm a diagnosis of AML, Develop molecular testing strategies to collect relevant information over the course of the AML treatment continuum, Recommend appropriate, safe management options for patients with diverse AML subtypes in collaboration with the wider oncology management team.

    • 1 hr 2 min
    Jay B. Wish, MD / Daniel W. Coyne, MD / Chilnille L. Milbrooks, MSN, FNP-C - Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse

    Jay B. Wish, MD / Daniel W. Coyne, MD / Chilnille L. Milbrooks, MSN, FNP-C - Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse

    Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

    • 1 hr 15 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press